<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03699111</url>
  </required_header>
  <id_info>
    <org_study_id>CTRIAL-IE 17-26</org_study_id>
    <nct_id>NCT03699111</nct_id>
  </id_info>
  <brief_title>Identification of New Patient Stratification Tools in MSS RAS mt mCRC</brief_title>
  <acronym>COLOSSUS</acronym>
  <official_title>Identification of New Patient Stratification Tools in Microsatellite Stable (MSS) RAS mt Metastatic Colorectal Cancer (mCRC) - COLOSSUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Trials Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a translational, multicentre and multinational study. The aim of this study is to
      identify new patient stratification tools in microsatellite stable RAS mutant metastatic
      Colorectal Cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The rational of COLOSSUS is to provide new and more effective stratification tools and
      therapeutic interventions, specifically tailored to MSS RAS mt mCRC patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2018</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stratification Tools</measure>
    <time_frame>4 years</time_frame>
    <description>Identification and technical (analytical) validation of new patient stratification tools (COLOSSUS subtypes) in MSS RAS mt mCRC using a novel integrative systems biomedicine multi-omics discovery framework.</description>
  </primary_outcome>
  <enrollment type="Anticipated">163</enrollment>
  <condition>Advanced Colorectal Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and tissue.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with stage IV MSS RAS mutant colorectal cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient Status

          -  Ability to give signed informed consent prior to any study specific procedures and
             willing and able to comply with the protocol

          -  Age ≥ 18 years

          -  ECOG status of ≤ 2

          -  At least 16 weeks of life expectancy at time of entry into the study

        Disease-related

          -  Histologically confirmed stage IV MSS RAS mt mCRC as per standard diagnostic tests

          -  Unresectable and measurable disease (at least one measurable target lesion) as per
             clinical and radiologic criteria (RECIST v.1.1)

          -  No prior chemotherapy for CRC in the metastatic setting, permitted in the neoadjuvant
             and adjuvant settings

          -  Scheduled to receive SOC chemotherapy with fluoropyrimidines and oxaliplatin +/-
             bevacizumab

          -  Availability of archival primary tumour tissue block (FFPE) obtained at the time of
             the initial diagnosis

        Exclusion Criteria:

          -  Patient with rectal cancer that has received any neo-adjuvant therapy before surgical
             resection of the primary tumour

          -  Patient who has received any investigational product within 28 days of the first day
             of palliative chemotherapy administration

          -  Patient with any significant history of non-compliance to medical treatments or with
             inability to grant reliable informed consent

          -  Patient with clinical or laboratory contraindication to receive SOC chemotherapy with
             fluoropyrimidines and oxaliplatin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cancer Trials Ireland, Innovation House, Glasnevin Dublin 11, Ireland</last_name>
    <phone>353 (1) 6677211</phone>
    <email>info@cancertrials.ie</email>
  </overall_contact>
  <location>
    <facility>
      <name>Private Practice Oncology, Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Fuxius, Dr. Med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital, Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Ebert, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private Practice Oncology, Speyer</name>
      <address>
        <city>Speyer</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Scheuer, Dr med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bon Secours Hospital, Cork</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Bird, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Morris, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ray McDermott, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tallaght University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ray McDermott, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Leonard, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Dienstmann, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Salazar Soler, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

